Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

hTERT analysis useful prognostic tool for lung cancer

Human telomerase reverse transcriptase (hTERT) analysis can be used as a prognostic tool for predicting progression of lung cancer, according to a new study published in the Journal of Thoracic Oncology.

The study involved 446 patients with advanced non-small cell lung cancer, whose blood samples were analysed.

Researchers determined levels of hTERT, as a surrogate of circulating DNA, before the patients underwent combination chemotherapy with cisplatin and docetaxel.

The study results showed that patients with hTERT levels below 49.8ng/ml had a median time to progression (TTP) of 6.3 months, compared to 4.9 months for patients with hTERT of more than 49.8ng/ml.

Patients having lower hTERT levels had higher overall survival, at 10.9 months versus 9.3 months for patients with higher hTERT.